A Double-blind, Randomised, Placebo-controlled, Flexible-dose of 50 mg/day to 400 mg/day, Phase IIIb Study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel XR) as an Add-on Therapy in Patients with Chronic Somatoform Pain Disorder
Phase of Trial: Phase III
Latest Information Update: 22 Jun 2016
At a glance
- Drugs Quetiapine (Primary)
- Indications Pain
- Focus Therapeutic Use
- 16 Sep 2011 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry.
- 16 Sep 2011 Actual initiation date changed from Feb 2011 to 22 Aug 2011 as reported by Australian New Zealand Clinical Trials Registry.
- 21 Jan 2011 New trial record